Lixte Biotechnology : 10-Q Filing Q1 2023

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


FORM 10-Q


... | May 10, 2023

Related Keywords

United States ,Netherlands ,Washington ,California ,Amsterdam ,Noord Holland ,Valencia ,Carabobo ,Venezuela ,Delaware ,China ,Broto ,Comunidad Autonoma De Aragon ,Spain ,Tennessee ,Tampa ,Florida ,Barcelona ,Comunidad Autonoma De Cataluna ,Madrid ,Spanish ,Javier Mart ,Julie Forman ,Johns Kovach ,Regina Brown ,Robertn Weingarten ,Stephen Forman ,Philip Palmedo ,Ericj Forman ,Medicamentosy Productos Sanitarios ,Gil Schwartzberg ,Morgan Stanley ,Company Annual Meeting Of Stockholders ,Nasdaq ,Company Vice ,Drug Administration ,Company Overview ,Company Annual Report On Form ,Party Transactions ,Morgan Stanley Smith Barney ,Securities Investor Protection Corporation ,Nasdaqstock Market ,Deposit Insurance Corporation ,Securities Exchange ,National Institute Of Neurologic Disorders ,Spanish Sarcoma Group Grupo Espa ,Research Institute Hospital Inc ,Spanish Sarcoma Group ,Exchange Commission ,Board Of Directors The Company ,Scientific Advisory Committee ,City Of Hope National Medical Center ,Exchange Commission On ,National Cancer Institute Pharmacologic Clinical Trial ,National Cancer Institute ,Nasdaq Stock Market ,Theradex Systems Inc ,Development Collaboration Agreement ,Clinical Trial Research Agreement ,National Institutes Of Health ,Spanish Sarcoma Research Group Grupo Espa ,Company Scientific Advisory Committee ,Company Board Of Directors ,European Union ,Netherlands Cancer Institute ,Consulting Corp ,Exchange Act ,Lixte Biotechnology Inc ,Spanish Agency For Medicines ,Pfizer ,City Of Hope Medical Foundation ,Clinical Research Support Agreement ,University Hospital Madrid ,Moffitt Cancer Center ,University Hospital ,Loncode Institute ,Lixte Biotechnology Holdings Inc ,Company Business Activities ,Sarah Cannon Research Institute ,Company Certificate Of Incorporation ,Health Products Agencia Espa ,Development Agreement ,Colorado Boulevard ,Zip Code ,Purchase Common Stock ,Securities Exchange Act ,Interactive Data File ,Regulations T ,Convertible Preferred Stock ,Months Ended March ,Lixte Biotechnology Holdings ,Lixte Biotechnology ,Annual Report ,Continued Listing ,Nasdaq Capital Market ,Nasdaq Listing Rule ,Listing Rule ,Nasdaq Capital ,Significant Accounting ,Chief Operating Decision Maker ,Chief Executive Officer ,Chief Scientific ,Morgan Stanley Wealth Management ,Federal Deposit Insurance Corporation ,Stanley Wealth Management ,Licensing Legal ,Filing Fees ,Financial Accounting Standards Board ,Accounting Standards Update ,Earnings Per Share ,Own Equity ,Certain Modifications ,Delaware Secretary ,Chief Scientific Officer ,Chief Medical Officer ,Chief Administrative Officer ,Vice President ,Chief Operating Officer ,Chief Financial Officer ,Incentive Plan ,Annual Meeting ,Average Remaining Contractual Life ,Effective August ,Investigational New Drug Application ,Collaboration Agreement ,Investigator Initiated Clinical Trial ,Grupo Espa ,Spanish Agency ,Health Products ,Agencia Espa ,Productos Sanitarios ,United States Dollar ,Effective January ,Hope National Medical Center ,Hope Medical Foundation ,Cancer Institute Pharmacologic Clinical ,Cooperative Research ,Theradex Systems ,Exclusive License Agreement ,License Agreement ,Licensed Patents ,Effective Date ,Nvalid Claims ,Significant Agreements ,Scientific Advisory ,Effective September ,Risks Associated ,Quarterly Report ,Securities Act ,Spanish Sarcoma Research Group ,Coordinating Investigator ,Accounting Policies ,Business Activities ,National Institute ,Neurologic Disorders ,National Institutes ,Capital Resources ,Exchange Act Rules ,Disclosure Controls ,Internal Control Over Financial ,Risk Factors ,Principal Executive Officer ,Principal Financial ,Accounting Officer ,Nc Stock Exchange ,News ,Information ,Press Release ,United ,Securities ,End ,Exchange ,Orm Lixt Us5393192027 ,